drugset / Trial / NCT05670028

Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization

NCT05670028 ↗

Phase 2 Unknown 100 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial aims to learn whether blood pressure (BP) guided by individualized cerebral autoregulation (CA) is safe and provides a better prognosis than a fixed target in patients with ischemic stroke after endovascular therapy. The BP of participants will be managed at least 48 hours after revascularization. Researchers will compare the CA-guided BP group with the fixed target BP group to mainly see if individualized BP could help more patients to have their neurological function improved at seven days.

Timeline

Start
2023-06-04
Primary completion
2026-01-31
Completion
2026-06-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Benazepril Unknown — —
Background Captopril Small molecule — —
Background Dopamine Small molecule — —
Background Irbesartan Small molecule — —
Background Labetalol Small molecule — —
Background Nifedipine Other / unclassified — —
Background Noradrenaline Unknown — —
Background Urapidil Small molecule — —
Background benidipine Small molecule — —